Article info
PDFClinical and epidemiological research
Extended report
Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still’s disease
- Correspondence to Professor Cem Gabay, Division of Rheumatology, Department of Internal Medicine Specialties, University Hospitals of Geneva, Geneva 1205, Switzerland; cem.gabay{at}hcuge.ch
Citation
Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still’s disease
Publication history
- Received October 27, 2017
- Revised January 19, 2018
- Accepted January 24, 2018
- First published February 22, 2018.
Online issue publication
April 12, 2023
Article Versions
- Previous version (2 August 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/